Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | AR | P10275 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24564604 | 1.00 | HRH3 (0.62) | HRH3ALDH1A1ALOX15MAPK1SIGMAR1 | |
| SCHEMBL24564554 | 1.00 | HRH3 (0.62) | HRH3ALDH1A1ALOX15MAPK1SIGMAR1 | |
| SCHEMBL24564641 | 1.00 | HRH3 (0.62) | HRH3ALDH1A1ALOX15MAPK1SIGMAR1 | |
| SCHEMBL24564724 | 1.00 | HRH3 (0.62) | HRH3ALDH1A1ALOX15MAPK1SIGMAR1 | |
| SCHEMBL24564687 | 0.99 | HRH3 (0.63) | HRH3ALDH1A1ALOX15MAPK1SIGMAR1 | |
| SCHEMBL24564654 | 0.99 | HRH3 (0.63) | HRH3ALDH1A1ALOX15MAPK1SIGMAR1 | |
| SCHEMBL24564551 | 0.99 | HRH3 (0.63) | HRH3ALDH1A1ALOX15MAPK1SIGMAR1 | |
| SCHEMBL24564601 | 0.89 | ALDH1A1 (0.51) | HRH3ALDH1A1ALOX15MAPK1SIGMAR1 | |
| SCHEMBL24580842 | 0.89 | HRH3 (0.61) | HRH3ALDH1A1SIGMAR1AR | |
| SCHEMBL24580944 | 0.88 | HRH3 (0.62) | HRH3ALDH1A1ALOX15MAPK1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022140464-A1 | COMPOUNDS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS BY TARGETING HLA-DQ2 | IMMUNOMOLECULAR THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220204471-A1 | Compounds and Methods for Treating Autoimmune Disorders by Targeting HLA-DQ2 | IMMUNOMOLECULAR THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204471-A1 | Compounds and Methods for Treating Autoimmune Disorders by Targeting HLA-DQ2 | HLA-DRB1, CD74, HLA-B | HRH3 393/4885ALDH1A1 3804/4885ALOX15 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.